Results 81 to 90 of about 11,407 (242)
International Journal of Dermatology, EarlyView.A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco +13 more
wiley +1 more source
Evaluation of rheumatologists’ knowledge of biosimilars
Advances in RheumatologyIntroduction Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists’ knowledge and perceptions of biosimilars.
Thayane Furtado Rolim Lima +3 more
doaj +1 more source
Denosumab discontinuation and fracture risk: getting the balance right
Internal Medicine Journal, EarlyView.Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley +1 more source
Biosimilars: A Multidisciplinary Perspective
, 2016 A biosimilar is an officially regulated and approved copy of an originator biologic therapy. Improved affordability and consequent wider patient access compared with biologics are a significant appeal of biosimilars.
Lukas, Milan +9 more
core +1 more source
The role of neutrophils in the pathophysiology of inflammatory bowel diseases
Periodontology 2000, EarlyView.Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens +8 more
wiley +1 more source
, 2015 INTRODUCTION: Rituximab is a monoclonal antibody targeting CD20, used to treat B cell malignancies and B cell-mediated autoimmune diseases. Rituximab has the largest market of any monoclonal antibody therapeutic.
Kay, Jonathan +2 more
core +1 more source
Archivos Argentinos de PediatriaBiosimilars are highly similar versions of already authorized biological drugs. A notable benefit of these is their significantly lower price compared to innovator drugs, which frees up healthcare resources and improves affordability. Leading regulatory agencies approve biosimilars after rigorous comparability studies, ensuring that there are no ...
Paulo, Cáceres Guido +1 more
openaire +2 more sources
Financial Toxicity Associated with Biological Medicines: A Scoping Review
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 81-93, July 2026.Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka +4 more
wiley +1 more source
Is Australia positioned to take advantage of biosimilars?
, 2014 Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small volume biological pharmaceuticals.
Lim, David (R19814)
core
, 2019 Siu et al. have comprehensively assessed the rapidly changing regulation and reimbursement environment for biologicals and biosimilars in Canada and the resultant ...
Allocati, Eleonora +2 more
core +1 more source